Navigation Links
Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade.
Date:7/31/2008

26.2 1,227.0

_________ _________

Total liabilities and shareholders' equity 4,202.8 4,330.1

_________ _________

Unaudited US GAAP results for the three and six months to June

30, 2008 Consolidated Statements of Operations

3 months 3 months 6 months 6 months

to June to June to June to June

30, 30, 30, 30,

2008 2007(1) 2008 2007(1)

$M $M $M $M

________ ________ ________ ________

Revenues:

Product sales 705.7 504.2 1,337.4 965.7

Royalties 64.8 64.0 129.9 123.5

Other revenues 5.1 6.7 10.5 13.9

________ _______ ________ ________

Total revenues 775.6 574.9 1,477.8 1,103.1

________ _______ ________ ________

Costs and expenses:

Cost of product sales(1) (2) (3) 142.9 74.0 233.2 141.3

Research and development(1) (3) 145.3 103.1 267.3 184.2

Selling, general and

administrative(1) (2) 428.8 280.6 763.3 519.2

Integration costs - 1.3 - 1.3

Gain on sale of product rights (9.1) (5.0) (16.7) (5.0)

In-process R&D charge 135.0 1,896.0 135.0 1,896.0

________ _______ ________ ________

Total operating expenses 842.9
'/>"/>

SOURCE Shire Ltd
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Shire Appoints Sylvie Gregoire President of Human Genetic Therapies Business
2. Shires ELAPRASE(R) (idursulfase) Approved in Japan for the Treatment of Hunter Syndrome
3. Shire Divests Non-Core Product Portfolio to Almirall
4. Correction: Shire plc: Third Quarter 2007 results date notification November 1, 2007
5. David Mott Appointed Non Executive Director at Shire
6. Shire plc: Board Changes
7. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
8. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
9. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
10. Texas Boy Receives Wheelchair From New Hampshire Couples Recently Deceased Granddaughter
11. Shire Engages Palio

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2009)...rstCall/ -- NeoStem, Inc. (NYSE Amex: NBS ), anno...to its shareholders, discussing the Company,s acqu...uticals Holdings, Inc. (CHBP), an integrated bio-p...ic of China. The merger gives NeoStem a controllin...td., CHBP,s primary operating subsidiary and a pro...
(Date:11/19/2009)... Aegera Therapeutics Inc. announced today the dosi...tudy of AEG35156, a targeted antisense therapeutic...dications. ,, The study, entitled "An Open-Labe...or of Apoptosis (XIAP) Antisense AEG35156 Given in...cin in AML Following Failure of a Single Standard ...
(Date:11/19/2009)...r 19 AFFiRiS AG will focus its,Alz...at an unexpectedly early,stage of development: the...hase II clinical trial early in 2010. This decisio...n of two Phase I trials with the candidates,AD01 a...e first interim,analysis of the secondary endpoint...
(Date:11/18/2009)... postage stamp that can sniff out poisonous gases ... reported in the Sept. 13 issue of the journal Na...he University of Illinois have developed an artifi...trial chemicals (TICs) that is simple, fast and in...ensor array could be useful in detecting high expo...
Breaking Biology Technology:NeoStem Outlines to Shareholders Near-term and Long-term Business Strategies Following Acquisition of Chinese Pharmaceutical Company 2NeoStem Outlines to Shareholders Near-term and Long-term Business Strategies Following Acquisition of Chinese Pharmaceutical Company 3Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML) 2AFFiRiS AG: Interim Analysis of Clinical Phase I Data Triggered Decision to Move Alzheimer's Vaccine Candidate AD02 into Clinical Phase II Testing 2AFFiRiS AG: Interim Analysis of Clinical Phase I Data Triggered Decision to Move Alzheimer's Vaccine Candidate AD02 into Clinical Phase II Testing 3Opto-electronic nose sniffs out toxic gases 2Opto-electronic nose sniffs out toxic gases 3
..., , , , Quantitative determination...ine procedure in many laboratories.,Protocols ar... in cell culture systems. The effects of growth,...factors,stimulation/inhibition by cytokines, de...ones and receptor,activity on proliferation, and...
..., , , , Roche Applied Science was ...tive technology allowing customers,to move away ...Even after 15 years and the,increasing availabil...antitative PCR-based technologies, the,DIG Syste...e to label and detect nucleic acids for multiple,...
..., , , , Since the first descriptio...hanism against invasion of foreign genes,appeare...ol for analyzing gene function in mammalian cells....that are,homologous to the suppressed gene. Thes...zed 21-mer RNA,molecules (each containing 19 com...
Other Biology Technology:Quantitative Measurement of Cell Proliferation,Using the BrdU ELISA: A Comparison,Between Colorimetric and Chemiluminescent Detection 2Quantitative Measurement of Cell Proliferation,Using the BrdU ELISA: A Comparison,Between Colorimetric and Chemiluminescent Detection 3Quantitative Measurement of Cell Proliferation,Using the BrdU ELISA: A Comparison,Between Colorimetric and Chemiluminescent Detection 4Quantitative Measurement of Cell Proliferation,Using the BrdU ELISA: A Comparison,Between Colorimetric and Chemiluminescent Detection 5Quantitative Measurement of Cell Proliferation,Using the BrdU ELISA: A Comparison,Between Colorimetric and Chemiluminescent Detection 6The DIG System Nonradioactive and,Highly Sensitive Detection of Nucleic Acids 2The DIG System Nonradioactive and,Highly Sensitive Detection of Nucleic Acids 3The DIG System Nonradioactive and,Highly Sensitive Detection of Nucleic Acids 4The DIG System Nonradioactive and,Highly Sensitive Detection of Nucleic Acids 5Quantification of siRNA Silencing Efficiency,Using the LightCycler System 2Quantification of siRNA Silencing Efficiency,Using the LightCycler System 3Quantification of siRNA Silencing Efficiency,Using the LightCycler System 4Quantification of siRNA Silencing Efficiency,Using the LightCycler System 5
(Date:11/19/2009)...d by Penn State,s Ross Hardison, T. Ming Chu Profe...ken a large step toward unraveling how regulatory ...uring development and growth. Working with collabo...el at Children,s Hospital of Philadelphia, they fo...cing red blood cells (erythrocytes). These cells c...
(Date:11/19/2009)...iller, University of Cincinnati professor of paleo..., and co-author Michael Foote of the University of...ue of Science with their paper, "Epicontinental ...ass Extinction and Origination." , For many year...istory of biodiversity have focused on charting th...
(Date:11/19/2009)..., Ill. A new statistical technique developed by r...ientists to scan a genome for specific gene-regula...the relevant transcription factors. The technique ...e genome and the fruit fly genome. , "Our statist... approaches, and is especially useful for investig...
Breaking Biology News(10 mins):New research into the mechanisms of gene regulation 2New research into the mechanisms of gene regulation 3New research into the mechanisms of gene regulation 4New research into the mechanisms of gene regulation 5Paleontologists find extinction rates higher in open-ocean settings during mass extinctions 2Paleontologists find extinction rates higher in open-ocean settings during mass extinctions 3Paleontologists find extinction rates higher in open-ocean settings during mass extinctions 4Technique finds gene regulatory sites without knowledge of regulators 2Frost 26amp 3B Sullivan to Discuss Investment Patterns in the Healthcare Industry in Free Webinar 59240 1Frost 26amp 3B Sullivan to Discuss Investment Patterns in the Healthcare Industry in Free Webinar 59240 2Nursing Students 3A Write Your Ticket to Madrid Spain 21 59236 1Nursing Students 3A Write Your Ticket to Madrid Spain 21 59236 2MDMA Board Unanimously Opposes Medical Device Tax 5366 1MDMA Board Unanimously Opposes Medical Device Tax 5366 2
...ts have found a way to induce cells to form parall...s tiny engineered blood vessels. , The researcher...nt by growing them on a surface with nano-scale pa...h in an online issue of Advanced Materials. , En...ed into tissues such as the kidneys, liver, heart ...
...ts have decreed that the federal government must c...hat will ensure the safety of the public and envir... times the length of recorded history., On Jan. 7...anning Nuclear Waste Management, a Case Study wil..., academia and the environmental community on the ...
...007 Researchers at Sarasota Memorial Health Care...ale Airway Stents for Emphysema) Trial, an interna...investigational treatment that may offer a signifi...ering with advanced widespread emphysema. The stud... involves creating pathways in the lung for trappe...
Other Biology News:MIT works toward engineered blood vessels 2Managing nuclear wastes for the millennia 2Researchers at Sarasota Memorial Health Care System to study airway bypass treatment for emphysema 2
...time PCR detection system holds 48 x 0.2 ml tubes,...pendently excites fluorescence (470-500 nm) for ea...s emitted light (523-543 nm and 540-700 nm). This ...ini thermal cycler. System dimensions are 18 x 32 ...
Cytomics FC 500 Series Flow Cytometry Systems from Beckman Coulter
Cellomics KineticScan HCS Reader from Beckman Coulter
...ng PULSin may be superior to transfection in some ...nsfection, with PULSin you can study lethal protei...ns in cells. Likewise, delivery of blocking antibo... RNA interference experiments. ,With PULSin you...
Biology Products: